|

Ramantamig Clinical Trials

2 actively recruiting trials across 2 locations

No change since July 2026

Also known as: BCMAxGPRC5DxCD3, JNJ-79635322

Pipeline

Phase 2: 2

Top Sponsors

  • Janssen Research & Development, LLC2

Indications

  • Multiple Myeloma2
  • Cancer2
  • Relapse Multiple Myeloma1
  • Refractory Multiple Myeloma1

Beverly Hills, California1 trial

A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma

Beverly Hills Cancer Center (BHCC)

Phase 2

San Francisco, California1 trial

A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

University of California San Francisco

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.